Targeted Genome Editing Tools for Disease Modeling and Gene Therapy
Mi Cai and Yi Yang
Affiliation: Novartis Institutes of Biomedical Research Inc., 100 Technology Square, Cambridge, MA 02139, USA.
The development of custom-designed nucleases (CDNs), including zinc finger nucleases (ZFNs) and transcription
activator-like effector nucleases (TALENs), has made it possible to perform precise genetic engineering in many cell
types and species. More recently, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
(Cas) system has been successfully employed for genome editing. These RNA-guided DNA endonucleases are shown to
be more efficient and flexible than CDNs and hold great potential for applications in both biological studies and medicine.
Here, we review the progress that has been made for all three genome editing technologies in modifying both cells and
model organisms, compare important aspects of each approach, and summarize the applications of these tools in disease
modeling and gene therapy. In the end, we discuss future prospects of the field.
Keywords: Zinc finger nucleases, TALENs, CRISPR, disease modeling, gene therapy, review.
Rights & PermissionsPrintExport